Nano Dimension Reports 2018 Third Quarter Financial Results

* Presented according to the change in our functional and presentation currency from NIS to U.S. dollars, effective January 1, 2018. The change in functional currency is accounted for prospectively from that date. Accordingly, comparative profit or loss figures have been translated into U.S. dollars using average exchange rates for the reporting periods.

**   Reclassified
 

Consolidated Statements of Changes in Equity (Unaudited)
(In thousands of USD)

  Share
capital
 Share premium Treasury shares Warrants Presentation currency translation reserve Capital reserve from transactions with controlling shareholders Capital reserve for share- based payments Accumulated loss Total
equity
                   
For the nine months ended September 30, 2018:                  
Balance as of January 1, 2018  2,307   45,722   (1,509)  33   1,431   63   6,241   (36,122)  18,166 
Issuance of ordinary shares, net  981   11,490   --   --   --   --   --   --   12,471 
Exercise of options  3   874   --   --   --   --   (877)  --   -- 
Expiration of options  --   1,104   --   (20)  --   --   (1,084)  --   -- 
Share-based payments  --   --   --   --   --   --   397   --   397 
Net loss     --       --       --       --       --       --       --       (11,521 )     (11,521 )
                                                                         
Balance as of September 30, 2018     3,291       59,190       (1,509 )     13       1,431       63       4,677       (47,643 )     19,513  
                                                                         
For the three months ended September 30, 2018:                                                                        

« Previous Page 1 | 2 | 3 | 4 | 5  Next Page »



© 2024 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us
ShareCG™ is a trademark of Internet Business Systems, Inc.

Report a Bug Report Abuse Make a Suggestion About Privacy Policy Contact Us User Agreement Advertise